Protalix BioTherapeutics (PLX)
Market Price (5/22/2026): $2.035 | Market Cap: $162.5 MilSector: Health Care | Industry: Biotechnology
Protalix BioTherapeutics (PLX)
Market Price (5/22/2026): $2.035Market Cap: $162.5 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 9.5%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 5.4%, FCF Yield is 8.0% Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -26% Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 26% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 17% Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Weak multi-year price returns3Y Excs Rtn is -88% | Key risksPLX key risks include [1] its heavy reliance on the commercial success of its approved product, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 9.5%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 5.4%, FCF Yield is 8.0% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -26% |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 26% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 17% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Weak multi-year price returns3Y Excs Rtn is -88% |
| Key risksPLX key risks include [1] its heavy reliance on the commercial success of its approved product, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Decline in Elelyso Product Sales. Revenues from selling goods, primarily Elelyso, decreased to $7.4 million for the first quarter of 2026, down from $10.0 million in the same period of 2025. This 26% decline was attributed to lower purchases by partners Pfizer and Fiocruz, which negatively impacted an established revenue stream.
2. Slower-than-Anticipated Elfabrio Commercial Ramp-Up. Despite the European Commission's approval in March 2026 of an every-four-weeks dosing regimen for Elfabrio and the subsequent $25 million milestone payment from Chiesi, the commercial uptake of Elfabrio in Europe is expected to be more significant in the second half of 2026 as country-level reimbursement approvals are secured. This suggests a slower initial commercial traction than some investors might have hoped for, especially given analyses noting Elfabrio's struggles against oral competition.
Show more
Stock Movement Drivers
Fundamental Drivers
The -13.2% change in PLX stock from 1/31/2026 to 5/21/2026 was primarily driven by a -69.3% change in the company's P/E Multiple.| (LTM values as of) | 1312026 | 5212026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.34 | 2.03 | -13.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 62 | 76 | 23.5% |
| Net Income Margin (%) | 8.7% | 20.1% | 130.1% |
| P/E Multiple | 34.4 | 10.6 | -69.3% |
| Shares Outstanding (Mil) | 79 | 80 | -0.7% |
| Cumulative Contribution | -13.2% |
Market Drivers
1/31/2026 to 5/21/2026| Return | Correlation | |
|---|---|---|
| PLX | -13.2% | |
| Market (SPY) | 7.6% | 34.7% |
| Sector (XLV) | -3.9% | 34.2% |
Fundamental Drivers
The -14.3% change in PLX stock from 10/31/2025 to 5/21/2026 was primarily driven by a -64.4% change in the company's P/E Multiple.| (LTM values as of) | 10312025 | 5212026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.37 | 2.03 | -14.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 62 | 76 | 23.3% |
| Net Income Margin (%) | 10.1% | 20.1% | 98.2% |
| P/E Multiple | 29.7 | 10.6 | -64.4% |
| Shares Outstanding (Mil) | 79 | 80 | -1.5% |
| Cumulative Contribution | -14.3% |
Market Drivers
10/31/2025 to 5/21/2026| Return | Correlation | |
|---|---|---|
| PLX | -14.3% | |
| Market (SPY) | 9.5% | 29.5% |
| Sector (XLV) | 3.6% | 22.1% |
Fundamental Drivers
The -33.9% change in PLX stock from 4/30/2025 to 5/21/2026 was primarily driven by a -85.6% change in the company's P/E Multiple.| (LTM values as of) | 4302025 | 5212026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.07 | 2.03 | -33.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 53 | 76 | 43.0% |
| Net Income Margin (%) | 5.5% | 20.1% | 265.6% |
| P/E Multiple | 73.5 | 10.6 | -85.6% |
| Shares Outstanding (Mil) | 70 | 80 | -12.1% |
| Cumulative Contribution | -33.9% |
Market Drivers
4/30/2025 to 5/21/2026| Return | Correlation | |
|---|---|---|
| PLX | -33.9% | |
| Market (SPY) | 35.5% | 21.3% |
| Sector (XLV) | 7.3% | 14.7% |
Fundamental Drivers
The -27.0% change in PLX stock from 4/30/2023 to 5/21/2026 was primarily driven by a -36.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 4302023 | 5212026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.78 | 2.03 | -27.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 48 | 76 | 60.3% |
| P/S Multiple | 3.0 | 2.1 | -28.9% |
| Shares Outstanding (Mil) | 51 | 80 | -36.0% |
| Cumulative Contribution | -27.0% |
Market Drivers
4/30/2023 to 5/21/2026| Return | Correlation | |
|---|---|---|
| PLX | -27.0% | |
| Market (SPY) | 85.6% | 16.4% |
| Sector (XLV) | 16.6% | 16.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| PLX Return | -77% | 65% | 30% | 6% | -4% | 12% | -45% |
| Peers Return | -31% | -25% | -27% | -0% | 14% | 1% | -56% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 9% | 98% |
Monthly Win Rates [3] | |||||||
| PLX Win Rate | 25% | 58% | 58% | 50% | 58% | 40% | |
| Peers Win Rate | 36% | 42% | 44% | 42% | 58% | 47% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| PLX Max Drawdown | -87% | -36% | -60% | -51% | -56% | -40% | |
| Peers Max Drawdown | -54% | -61% | -59% | -56% | -57% | -31% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: AMGN, IBIO, FDMT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/21/2026 (YTD)
How Low Can It Go
| Event | PLX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -41.6% | -18.8% |
| % Gain to Breakeven | 71.2% | 23.1% |
| Time to Breakeven | 147 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -17.0% | -7.8% |
| % Gain to Breakeven | 20.4% | 8.5% |
| Time to Breakeven | 36 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -10.1% | -9.5% |
| % Gain to Breakeven | 11.2% | 10.5% |
| Time to Breakeven | 20 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -11.0% | -24.5% |
| % Gain to Breakeven | 12.3% | 32.4% |
| Time to Breakeven | 8 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -46.3% | -33.7% |
| % Gain to Breakeven | 86.2% | 50.9% |
| Time to Breakeven | 39 days | 140 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -50.0% | -3.7% |
| % Gain to Breakeven | 99.9% | 3.9% |
| Time to Breakeven | 34 days | 6 days |
In The Past
Protalix BioTherapeutics's stock fell -41.6% during the 2025 US Tariff Shock. Such a loss loss requires a 71.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | PLX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -41.6% | -18.8% |
| % Gain to Breakeven | 71.2% | 23.1% |
| Time to Breakeven | 147 days | 79 days |
| 2020 COVID-19 Crash | ||
| % Loss | -46.3% | -33.7% |
| % Gain to Breakeven | 86.2% | 50.9% |
| Time to Breakeven | 39 days | 140 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -50.0% | -3.7% |
| % Gain to Breakeven | 99.9% | 3.9% |
| Time to Breakeven | 34 days | 6 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -35.4% | -17.9% |
| % Gain to Breakeven | 54.8% | 21.8% |
| Time to Breakeven | 221 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -70.6% | -53.4% |
| % Gain to Breakeven | 239.6% | 114.4% |
| Time to Breakeven | 157 days | 1085 days |
| Summer 2007 Credit Crunch | ||
| % Loss | -43.5% | -8.6% |
| % Gain to Breakeven | 77.0% | 9.5% |
| Time to Breakeven | 2 days | 47 days |
In The Past
Protalix BioTherapeutics's stock fell -41.6% during the 2025 US Tariff Shock. Such a loss loss requires a 71.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Protalix BioTherapeutics (PLX)
AI Analysis | Feedback
1. An 'Impossible Foods for pharmaceuticals,' using plants to produce complex protein drugs for human diseases.
2. A biotech company like a specialized Amgen, but 'growing' its therapeutic proteins in plant cells rather than traditional bioreactors.
3. A modern Genzyme (now part of Sanofi), but one that uses a unique plant cell system to manufacture its rare disease treatments.
AI Analysis | Feedback
```html- Elelyso: A treatment for Gaucher disease.
- PRX-102: A therapeutic protein candidate in late-stage clinical trials for the treatment of Fabry disease.
- PRX-110: A proprietary plant cell recombinant form of human deoxyribonuclease I for the treatment of cystic fibrosis.
- PRX-115: A plant cell-expressed recombinant PEGylated Uricase for the treatment of gout.
- PRX-119: A plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases.
AI Analysis | Feedback
Protalix BioTherapeutics (PLX) sells primarily to other companies and organizations through strategic agreements and partnerships for the development, commercialization, and distribution of its therapeutic proteins.
Its major customers/partners include:
- Pfizer (Symbol: PFE)
- Chiesi Farmaceutici S.p.A.
- Fundação Oswaldo Cruz (Fiocruz)
AI Analysis | Feedback
NULLAI Analysis | Feedback
Protalix BioTherapeutics (PLX) has a management team with extensive experience in the pharmaceutical and biotechnology industries.Dror Bashan
President and Chief Executive Officer Mr. Dror Bashan was appointed President and Chief Executive Officer and a Director of Protalix BioTherapeutics in June 2019. He brings over 25 years of experience in the pharmaceutical industry to his role. Prior to joining Protalix, Mr. Bashan held several senior positions at Teva Pharmaceutical Industries Ltd. from 1998 to 2018. His most recent role at Teva was Senior Vice President of Global Business Development, where he was involved in strategic alliances, mergers and acquisitions (M&A), and the acquisition and divestiture of assets. Notably, he oversaw Teva's largest divestiture process of global women's health assets in early 2018. Mr. Bashan began his career as a Senior Business Analyst at Bank Leumi in September 1993. He holds a Bachelor of Arts in Economics and Business Management and a Master of Business Administration in Finance and Marketing from Tel Aviv University.Gilad Mamlok
Senior Vice President and Chief Financial Officer Mr. Gilad Mamlok serves as the Senior Vice President and Chief Financial Officer of Protalix BioTherapeutics. Specific details regarding his background, such as founding or managing other companies, selling companies to acquirers, or a pattern of managing private equity-backed companies, were not readily available in the provided information.Einat Brill Almon, Ph.D.
Senior Vice President, Product Development Dr. Einat Brill Almon joined Protalix Ltd. in December 2004 as Vice President, Product Development, and continued in this role with Protalix BioTherapeutics after December 31, 2006. She possesses extensive experience in managing life science projects and companies within biotechnology and agrobiotech sectors. Her expertise spans clinical, device, and scientific software development, coupled with a strong background in Intellectual Property. Before her tenure at Protalix Ltd., from 2001 to 2004, Dr. Almon was the Director of R&D and IP at Biogenics Ltd., an Israeli company that developed an autologous platform for tissue-based protein drug delivery and was a wholly-owned subsidiary of Medgenics Inc. Dr. Almon trained as a biotechnology patent agent at prominent IP firms in Israel. She earned her Ph.D. and M.Sc. in molecular biology of cancer research from the Weizmann Institute of Science, a B.Sc. from the Hebrew University, and completed Post-Doctoral research in plant molecular biology at the Hebrew University.Yaron Naos
Senior Vice President, Operations Mr. Yaron Naos holds the position of Senior Vice President of Operations at Protalix BioTherapeutics.Fernando Sallés
Chief Business Officer Mr. Fernando Sallés serves as the Chief Business Officer for Protalix BioTherapeutics.AI Analysis | Feedback
The key risks to Protalix BioTherapeutics (PLX) include:
- Clinical Development and Regulatory Approval Risk: A significant portion of Protalix's future growth and revenue potential depends on the successful completion of clinical trials and subsequent regulatory approvals for its pipeline products. Specifically, PRX-102, which is in the last stage of clinical trials for Fabry disease, represents a critical asset. Failure to demonstrate efficacy or safety, encountering unexpected side effects during trials, or inability to secure regulatory approvals would severely impact the company's ability to bring new products to market and generate substantial revenue.
- Commercialization and Market Competition Risk: Even if Protalix's pipeline products receive regulatory approval, there is no guarantee of successful commercialization or significant market acceptance. The company's commercialized product, Elelyso, and future products like PRX-102, operate in competitive markets for rare diseases. Risks include intense competition from existing therapies or other companies developing similar treatments, pricing pressures, challenges in securing market access and reimbursement, and difficulties in achieving widespread physician and patient adoption.
- Reliance on a Limited Product Pipeline: Protalix's future prospects are heavily dependent on the successful development and commercialization of a few key pipeline candidates, most notably PRX-102. While Elelyso is on the market, the company's long-term growth is tied to these developmental assets. Should these key candidates fail in trials, face significant delays, or underperform commercially, the company has a limited number of other late-stage products to mitigate the impact on its financial performance and strategic outlook.
AI Analysis | Feedback
nullAI Analysis | Feedback
Protalix BioTherapeutics (PLX) develops and commercializes recombinant therapeutic proteins for various diseases. The addressable markets for their main products are outlined below:- Elelyso (Gaucher disease): The global market for Gaucher disease treatments was valued at approximately USD 1.66 billion in 2024 and is projected to reach USD 2.02 billion by 2032. Other estimates place the global market at USD 1.8 billion in 2024, with a projected growth to USD 3.0 billion by 2033. The U.S. market specifically for Gaucher disease drugs was valued at USD 645.7 million in 2024. North America is a dominant region in this market.
- PRX-102 (Fabry disease): The global Fabry disease treatment market was estimated at USD 2.54 billion in 2023 and is projected to reach USD 4.93 billion by 2030. Other reports suggest the global market was approximately USD 1.7 billion in 2024, with expectations for significant growth through 2034, or USD 2.4 billion in 2024, potentially reaching USD 4.9 billion by 2033. In 2024, the United States market for Fabry disease therapeutics was estimated at around USD 880 million. North America held the largest revenue share, with the U.S. accounting for 90.1% of that share in 2023.
- PRX-110 (Cystic Fibrosis): The global cystic fibrosis therapeutics market was estimated at USD 10.3 billion in 2024 and is projected to grow to USD 22.7 billion by 2030. Other analyses suggest a market size of USD 11.81 billion in 2025, increasing to USD 13.49 billion in 2026, with a projection to reach about USD 44.72 billion by 2035. North America held the largest revenue share of 59.8% in the global market in 2024.
- PRX-115 (Gout): The global gout disease treatment market was valued at approximately USD 2.76 billion in 2023 and is predicted to reach about USD 5.53 billion by 2032. Another source indicates the market size is expected to be around USD 5.4 billion by 2032, growing from USD 2.4 billion in 2022. The Gout Therapeutics Market is projected to be USD 4.24 billion in 2025, reaching USD 6.67 billion by 2031. The U.S. gout therapeutics market was valued at USD 1.40 billion in 2024. North America is considered the most lucrative market, holding the largest market share of 39.4%.
- PRX-119 (NETs-related diseases): The global Neuroendocrine Tumors (NETs) treatment market was valued at USD 2.45 billion in 2025 and is projected to grow to USD 4.12 billion by 2034. Other estimates indicate the market was valued at USD 3.57 billion in 2023 and is expected to reach USD 6.94 billion by 2030. The global neuroendocrine tumor (NET) treatment industry was valued at USD 2.5 billion in 2023 and is anticipated to reach USD 5.5 billion by 2032. North America dominated the NET treatment market in 2023 with a revenue of USD 1.1 billion, with projections to reach USD 2.3 billion by 2032.
AI Analysis | Feedback
Protalix BioTherapeutics (PLX) is expected to experience future revenue growth over the next 2-3 years, driven by several key factors:
-
Expanding Sales and Market Penetration of Elfabrio (PRX-102) for Fabry Disease: Elfabrio, approved by the FDA and EMA in May 2023, is a significant revenue contributor for Protalix. The product generated approximately $29.3 million in sales to partner Chiesi in fiscal year 2024, contributing to a 31% rise in product revenues that year due to inventory builds. For the first nine months of 2025, Elfabrio sales accounted for $18.6 million of the company's $43.1 million in product sales. A recent positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending an every-four-weeks (E4W) dosing regimen for stable adult Fabry patients in Europe, with potential European Commission approval by March 2026, could enhance patient quality of life and strengthen Elfabrio's competitive standing in the market. Furthermore, Protalix is eligible to receive substantial regulatory and commercial milestone payments, as well as tiered royalties ranging from 15% to 40% on net sales from Chiesi for PRX-102 in the United States.
-
Continued Growth in Elelyso Sales for Gaucher Disease: Elelyso, approved in 2012 for Gaucher disease, continues to be a steady revenue stream. Annual global sales for Elelyso range from $16 million to $23 million. In 2024, sales through partners Pfizer and Fiocruz increased by 3%. For the first nine months of 2025, Elelyso sales reached $24.6 million. The market for Elelyso is expected to grow due to factors such as advancements in recombinant biologics, expanded home infusion services, increasing diagnosis rates, and improved reimbursement frameworks.
-
Advancement of PRX-115 for Gout into Phase 2 Clinical Trials: The progression of PRX-115, a proprietary plant cell-expressed recombinant PEGylated Uricase for gout, represents a potential future revenue driver. The company completed Phase I clinical trials in 2024. Protalix submitted an Investigational New Drug (IND) for PRX-115 in October 2025, which has since become effective, and plans to initiate a Phase II clinical trial for PRX-115 in the second half of 2025, with top-line results anticipated in the third quarter of 2027. Protalix's CEO has described PRX-115 as a potential "best-in-class therapy."
-
Receipt of Milestone Payments and Royalties from Strategic Partnerships: Protalix stands to benefit from additional milestone payments and royalties stemming from its existing partnerships. The company previously received a $20 million regulatory milestone payment in fiscal year 2023 tied to the FDA approval of Elfabrio. There is also a potential $25 million milestone payment linked to the European Union approval of Elfabrio's new dosing regimen. The extensive partnership with Chiesi for PRX-102 also includes significant potential regulatory and commercial milestone payments and tiered royalties on net sales.
AI Analysis | Feedback
Share Issuance
- Protalix BioTherapeutics' shares outstanding increased by 15.89% in one year.
- The company had 80.42 million shares outstanding in the last 12 months.
Inbound Investments
- In 2023, Protalix BioTherapeutics recorded $25.1 million in revenues from license and R&D services, predominantly from its license and supply agreements with Chiesi Farmaceutici S.p.A., which included $20 million.
Capital Expenditures
- Capital expenditures for the last 12 months amounted to approximately $1.66 million.
- In the most recent quarter, capital expenditures totaled approximately $0.498 million.
- These expenditures support the development, production, and commercialization of recombinant therapeutic proteins based on the company's proprietary ProCellEx plant cell-based protein expression system.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Protalix BioTherapeutics Earnings Notes | 12/16/2025 | |
| How Low Can Protalix BioTherapeutics Stock Really Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to PLX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 5.36 |
| Mkt Cap | 0.4 |
| Rev LTM | 82 |
| Op Inc LTM | -5 |
| FCF LTM | -5 |
| FCF 3Y Avg | -7 |
| CFO LTM | -3 |
| CFO 3Y Avg | -6 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 18.4% |
| Rev Chg 3Y Avg | 24.3% |
| Rev Chg Q | 233.7% |
| QoQ Delta Rev Chg LTM | 2.4% |
| Op Inc Chg LTM | 26.8% |
| Op Inc Chg 3Y Avg | 1.6% |
| Op Mgn LTM | -88.8% |
| Op Mgn 3Y Avg | -8,411.5% |
| QoQ Delta Op Mgn LTM | -6.3% |
| CFO/Rev LTM | -63.5% |
| CFO/Rev 3Y Avg | -8,109.6% |
| FCF/Rev LTM | -64.9% |
| FCF/Rev 3Y Avg | -8,311.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.4 |
| P/S | 5.8 |
| P/Op Inc | 2.4 |
| P/EBIT | 2.2 |
| P/E | 3.4 |
| P/CFO | 3.1 |
| Total Yield | -2.5% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -16.9% |
| D/E | 0.0 |
| Net D/E | -0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -5.1% |
| 3M Rtn | -16.2% |
| 6M Rtn | 9.6% |
| 12M Rtn | 86.4% |
| 3Y Rtn | -28.4% |
| 1M Excs Rtn | -9.0% |
| 3M Excs Rtn | -22.7% |
| 6M Excs Rtn | -8.4% |
| 12M Excs Rtn | 50.7% |
| 3Y Excs Rtn | -110.1% |
Price Behavior
| Market Price | $2.03 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 05/15/1998 | |
| Distance from 52W High | -35.6% | |
| 50 Days | 200 Days | |
| DMA Price | $2.19 | $2.13 |
| DMA Trend | up | down |
| Distance from DMA | -7.1% | -4.7% |
| 3M | 1YR | |
| Volatility | 62.8% | 66.8% |
| Downside Capture | 352.40 | 162.17 |
| Upside Capture | 86.80 | 134.06 |
| Correlation (SPY) | 43.8% | 30.3% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.66 | 2.36 | 1.54 | 1.46 | 1.35 | 0.76 |
| Up Beta | 1.68 | 1.29 | 0.74 | 0.62 | -0.26 | 0.40 |
| Down Beta | 4.31 | 3.30 | 4.09 | 3.25 | 2.24 | 0.82 |
| Up Capture | 69% | 152% | 133% | 107% | 158% | 59% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 11 | 19 | 31 | 61 | 123 | 343 |
| Down Capture | 468% | 331% | 121% | 133% | 171% | 104% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 10 | 22 | 30 | 58 | 113 | 349 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PLX | |
|---|---|---|---|---|
| PLX | 20.5% | 66.8% | 0.56 | - |
| Sector ETF (XLV) | 12.0% | 14.7% | 0.55 | 20.9% |
| Equity (SPY) | 26.8% | 12.1% | 1.67 | 30.1% |
| Gold (GLD) | 37.5% | 26.8% | 1.16 | 11.6% |
| Commodities (DBC) | 43.5% | 18.6% | 1.80 | -11.6% |
| Real Estate (VNQ) | 12.0% | 13.4% | 0.59 | 14.2% |
| Bitcoin (BTCUSD) | -27.2% | 41.8% | -0.65 | 19.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PLX | |
|---|---|---|---|---|
| PLX | -5.4% | 68.3% | 0.21 | - |
| Sector ETF (XLV) | 5.4% | 14.6% | 0.19 | 14.3% |
| Equity (SPY) | 13.8% | 17.0% | 0.64 | 17.0% |
| Gold (GLD) | 19.3% | 18.0% | 0.87 | 6.7% |
| Commodities (DBC) | 10.8% | 19.4% | 0.44 | 1.7% |
| Real Estate (VNQ) | 3.8% | 18.8% | 0.10 | 15.3% |
| Bitcoin (BTCUSD) | 9.3% | 55.6% | 0.37 | 11.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PLX | |
|---|---|---|---|---|
| PLX | -12.5% | 79.2% | 0.19 | - |
| Sector ETF (XLV) | 9.8% | 16.5% | 0.48 | 13.5% |
| Equity (SPY) | 15.5% | 17.9% | 0.74 | 15.3% |
| Gold (GLD) | 13.2% | 16.0% | 0.68 | 4.9% |
| Commodities (DBC) | 7.8% | 17.9% | 0.35 | 5.6% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.22 | 12.1% |
| Bitcoin (BTCUSD) | 67.3% | 66.9% | 1.06 | 7.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/18/2026 | -20.8% | -25.8% | -17.6% |
| 11/13/2025 | -9.8% | -17.3% | -18.7% |
| 8/14/2025 | -5.6% | -2.5% | 12.4% |
| 3/17/2025 | 9.4% | 11.2% | 17.0% |
| 11/14/2024 | 13.7% | 36.3% | 45.2% |
| 8/14/2024 | -10.6% | -8.6% | 1.9% |
| 3/14/2024 | -9.9% | -11.8% | -22.4% |
| 11/6/2023 | -18.4% | -27.6% | -16.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 11 | 11 |
| # Negative | 11 | 10 | 10 |
| Median Positive | 2.3% | 7.5% | 12.4% |
| Median Negative | -9.3% | -11.3% | -16.9% |
| Max Positive | 14.5% | 48.6% | 45.2% |
| Max Negative | -20.8% | -27.6% | -26.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/13/2026 | 10-Q |
| 12/31/2025 | 03/18/2026 | 10-K |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/09/2025 | 10-Q |
| 12/31/2024 | 03/17/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/10/2024 | 10-Q |
| 12/31/2023 | 03/14/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/27/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q1 2026 Earnings Reported 5/13/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Total Revenue | 78.00 Mil | 80.50 Mil | 83.00 Mil | 0 | Affirmed | Guidance: 80.50 Mil for 2026 | |
| 2026 Elfabrio Revenue (excluding milestones) | 33.00 Mil | 34.00 Mil | 35.00 Mil | 0 | Affirmed | Guidance: 34.00 Mil for 2026 | |
| 2026 Elelyso Revenue | 20.00 Mil | 21.50 Mil | 23.00 Mil | 0 | Affirmed | Guidance: 21.50 Mil for 2026 | |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.